Literature DB >> 15180615

Risk behaviours and benign prostatic hyperplasia.

D Kang1, G L Andriole, R C Van De Vooren, D Crawford, D Chia, D A Urban, D Reding, W-Y Huang, R B Hayes.   

Abstract

OBJECTIVE: To identify risk factors for benign prostatic hyperplasia (BPH). SUBJECTS AND METHODS: Medical history data, including reported urological conditions and treatments, and risk factor data were collected from 34 694 participants in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, a randomized controlled trial designed to evaluate methods for the early detection of cancer.
RESULTS: Asian men had the lowest risks (odds ratio, 95% confidence interval) for nocturia (0.7, 0.5-0.9), physician-diagnosed BPH (0.3, 0.2-0.5) and transurethral prostatectomy (TURP, 0.2, 0.1-0.6), while risks for Whites and Blacks were similar for most measures of BPH. Greater alcohol intake was associated with decreased nocturia (P trend = 0.002), BPH (P trend < 0.001) and TURP (P trend < 0.001). Current tobacco use was associated with decreased nocturia (0.8, 0.7-0.9), BPH (0.7, 0.6-0.8) and TURP (0.6, 0.4-0.8) but dose-response patterns were weak.
CONCLUSION: Asian-Americans have the lowest risk of clinical BPH. Alcohol and possibly cigarettes are related to a lower risk for BPH.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15180615     DOI: 10.1111/j.1464-410X.2004.04839.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  14 in total

Review 1.  Dietary patterns, supplement use, and the risk of benign prostatic hyperplasia.

Authors:  Kenneth S Poon; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

2.  Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Siobhan Sutcliffe; Robert L Grubb Iii; Elizabeth A Platz; Lawrence R Ragard; Thomas L Riley; Sally S Kazin; Richard B Hayes; Ann W Hsing; Gerald L Andriole
Journal:  BJU Int       Date:  2012-03-19       Impact factor: 5.588

3.  Nonsteroidal antiinflammatory drug use and lower urinary tract symptoms: results from the Boston area community health survey.

Authors:  Margaret A Gates; Susan A Hall; Gretchen R Chiu; Varant Kupelian; Mary P Fitzgerald; Carol L Link; John B McKinlay
Journal:  Am J Epidemiol       Date:  2011-02-28       Impact factor: 4.897

4.  Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Authors:  Jeannette M Schenk; Gregory S Calip; Catherine M Tangen; Phyllis Goodman; J Kellogg Parsons; Ian M Thompson; Alan R Kristal
Journal:  Am J Epidemiol       Date:  2012-06-28       Impact factor: 4.897

5.  Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men.

Authors:  J Kellogg Parsons; Jaclyn Bergstrom; Elizabeth Barrett-Connor
Journal:  BJU Int       Date:  2007-11-13       Impact factor: 5.588

Review 6.  Inflammatory mediators in the development and progression of benign prostatic hyperplasia.

Authors:  Cosimo De Nunzio; Fabrizio Presicce; Andrea Tubaro
Journal:  Nat Rev Urol       Date:  2016-09-30       Impact factor: 14.432

7.  Lower urinary tract symptoms in relation to region of birth in 95,393 men living in Australia: the 45 and Up Study.

Authors:  Isabel Latz; Marianne Weber; Rosemary Korda; David Smith; Mark Clements; Manish Patel; Terry Dwyer; Gabriella Tikellis; Emily Banks
Journal:  World J Urol       Date:  2012-09-02       Impact factor: 4.226

8.  Benign prostatic hyperplasia: from bench to clinic.

Authors:  Tag Keun Yoo; Hee Ju Cho
Journal:  Korean J Urol       Date:  2012-03-19

Review 9.  Epidemiology of lower urinary tract symptoms: emphasis on the status in Korea.

Authors:  Hakmin Lee; Seong Jin Jeong
Journal:  Korean J Urol       Date:  2014-05-12

Review 10.  Nonsteroidal anti-inflammatory drugs and prostatic diseases.

Authors:  Hitoshi Ishiguro; Takashi Kawahara
Journal:  Biomed Res Int       Date:  2014-05-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.